Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells
暂无分享,去创建一个
Hailiang Wang | Xiangyang Leng | Wei-min Li | Xu-dong Zhang | Chunlan Wang | Shulin Lian | Jingbin Feng | Jinliang Li
[1] Zhilan Peng,et al. MG132, a proteasome inhibitor, induces apoptosis in tumor cells , 2013, Asia-Pacific journal of clinical oncology.
[2] Jennifer L. Thompson. Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma , 2013, The Annals of pharmacotherapy.
[3] C. Moskaluk,et al. Phase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] K. O'Byrne,et al. Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] D. Hanseman,et al. Prospective Evaluation of the Toxicity Profile of Proteasome Inhibitor–Based Therapy in Renal Transplant Candidates and Recipients , 2012, Transplantation.
[6] J. Baehring,et al. Glioblastoma multiforme: overview of current treatment and future perspectives. , 2012, Hematology/oncology clinics of North America.
[7] I. Rosas,et al. Autophagy in Idiopathic Pulmonary Fibrosis , 2012, PloS one.
[8] H. Saya,et al. Molecular biology of glioma. , 2012, Advances in experimental medicine and biology.
[9] R. Perez-soler,et al. Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] J. Pignon,et al. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. , 2012, Lung cancer.
[11] A. Shanker,et al. Development of Proteasome Inhibitors as Therapeutic Drugs. , 2012, Journal of clinical & cellular immunology.
[12] S. Bhaumik,et al. The 26S proteasome complex: an attractive target for cancer therapy. , 2012, Biochimica et biophysica acta.
[13] S. Leenstra,et al. Recent advances in the molecular understanding of glioblastoma , 2009 .
[14] Q. Dou,et al. Advances in the understanding of mechanisms and therapeutic use of bortezomib. , 2011, Discovery medicine.
[15] S. Qiu,et al. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis , 2011, Autophagy.
[16] Jia Fan,et al. Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation , 2011, Clinical Cancer Research.
[17] I. Pollack,et al. Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL, Mediated by Inhibition of the NF-κB Signaling Pathway , 2011, Molecular Cancer Therapeutics.
[18] A. Wen,et al. Autophagy is a therapeutic target in anticancer drug resistance. , 2010, Biochimica et biophysica acta.
[19] K. Dalby,et al. Targeting the pro-death and pro-survival functions of autophagy as novel therapeutic strategies in cancer , 2010, Autophagy.
[20] S. Pédeboscq,et al. Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. , 2008, Journal of experimental therapeutics & oncology.
[21] J. Cleveland,et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. , 2007, Blood.
[22] G. Evan,et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. , 2007, The Journal of clinical investigation.
[23] Kevin Bray,et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. , 2006, Cancer cell.
[24] M. Boccadoro,et al. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies , 2006, Nature Clinical Practice Oncology.
[25] M. Carducci,et al. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] Rafael Fonseca,et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] G. Giaccone,et al. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies , 2005, Cancer.
[28] Junying Yuan,et al. Autophagy in cell death: an innocent convict? , 2005, The Journal of clinical investigation.
[29] P. Elliott,et al. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] D. Chauhan,et al. Proteasome inhibition in multiple myeloma: therapeutic implication. , 2005, Annual review of pharmacology and toxicology.
[31] T. Sayers,et al. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy , 2005, Cancer Immunology, Immunotherapy.
[32] K. Neville,et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] C. López-Otín,et al. Autophagy: molecular mechanisms, physiological functions and relevance in human pathology , 2004, Cellular and Molecular Life Sciences CMLS.
[34] K. Hoang-Xuan,et al. Primary brain tumours in adults , 2003, The Lancet.
[35] J. Shapiro. Genetic alterations associated with adult diffuse astrocytic tumors. , 2002, American journal of medical genetics.
[36] S. Soignet,et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] B. Pikul,et al. Gliomas--past, present, and future. , 1999, Clinical neurosurgery.